Loading
A phase 2 trial of camrelizumab and eribulin in triple-negative breast cancer, run by Fudan University, not yet recruiting.
JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC is a phase 2, randomised interventional study registered as NCT06731153 by Fudan University, with a registry enrolment figure of 40 participants, started 2024-12 and due to reach its primary completion in 2027-06. Interventions recorded: Ivarmacitinib; Camrelizumab (SHR-1210); Eribulin. Conditions listed: Triple Negative Breast Cancer (TNBC); Metastatic Breast Cancer. Triple-negative eligibility wording from the registry: "Metastatic or locally advanced, histologically documented TNBC;". Sites: China. No results are recorded here; the registry entry is the source.
Shares Camrelizumab, Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Camrelizumab, Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Immune checkpoint inhibitors and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Eribulin, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Camrelizumab, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.